This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignees: Chinese Academy of Sciences, Shanghai Haihe Pharmaceutical Co., Ltd.. Active years: 2022.
Company Filing History:
1 out of 3,341 
1 out of 9 Years Active: 2022
Title: Ning Shen: Innovator in ERK Kinase Inhibition
Introduction
Ning Shen is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit ERK kinases. His work has implications for various therapeutic applications.
Latest Patents
Ning Shen holds a patent for a compound having ERK kinase inhibitory activity. The invention relates to a compound of formula (I), wherein variables are defined in the specification. This compound acts as an inhibitor of ERK kinases, specifically ERK1 and/or ERK2. The patent also covers the use of this compound, a method for preparing it, and a pharmaceutical composition containing the compound.
Career Highlights
Throughout his career, Ning Shen has worked with prominent organizations such as Shanghai Haihe Pharmaceutical Co., Ltd. and the Chinese Academy of Sciences. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Ning Shen has collaborated with several professionals in his field, including Lei Li and Meiyu Geng. These collaborations have enriched his research and fostered innovation in the development of new therapeutic compounds.
Conclusion
Ning Shen's work in the area of ERK kinase inhibition showcases his dedication to advancing pharmaceutical science. His patent and collaborations highlight his role as an influential inventor in this important field.